Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass.

The article presents a study which assesses the effectiveness of zoledronic acid in preventing bone loss among women under postmenopausal stage with low bone mass. Women under postmenopausal stage with low bone mass are given with zoledronic acid intravenously. Results show that zoledronic acid medication decreases bone turnover. It concludes that a 5mg dosage of zoledronic acid a year prevents bone loss for 2 years and is allowed to women under postmenstrual stage.